Cargando…
Innovative regenerative medicines in the EU: a better future in evidence?
BACKGROUND: Despite a steady stream of headlines suggesting they will transform the future of healthcare, high-tech regenerative medicines have, to date, been quite inaccessible to patients, with only eight having been granted an EU marketing licence in the last 7 years. Here, we outline some of the...
| Autores principales: | , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
BioMed Central
2017
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5341436/ https://www.ncbi.nlm.nih.gov/pubmed/28270209 http://dx.doi.org/10.1186/s12916-017-0818-4 |